Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug clearance

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,061 result(s) found for: Drug clearance. Displaying page 8 of 104.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2012-002777-56 Sponsor Protocol Number: ML28470 Start Date*: 2012-08-20
    Sponsor Name:ROCHE
    Full Title: Cross-sectional multicenter study evaluating the IL28B polymorphism in patients with HBeAg-negative chronic hepatitis B treated with pegylated interferon alfa-2a in the course of Peg.Be.Liver study
    Medical condition: HBeAg-negative chronic hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10008910 Chronic hepatitis B LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-004760-21 Sponsor Protocol Number: BIO-TAILOR Start Date*: 2020-10-07
    Sponsor Name:FONDAZIONE MELANOMA ONLUS
    Full Title: Dabrafenib and trametinib in circulating free DNA BRAFV600 mutated metastatic melanoma patients: a prospective phase II, open label, multicentre study – (Bioliquid TAILOR study – BIO-TAILOR)
    Medical condition: Metastatic melanoma patients with tissue BRAFWT signature and a molecular shift to circulating free DNA BRAF mutated positive melanomas upon progression to an anti PD-1 therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-002377-28 Sponsor Protocol Number: APHP210090 Start Date*: 2022-10-17
    Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP)
    Full Title: Prognostic impact of early oseltamivir carboxylate underdosing in patients admitted to the ICU with severe influenza: a multicenter prospective cohort study
    Medical condition: Adult patients admitted to the ICU for management of severe influenza infection requiring orotracheal intubation for invasive mechanical ventilation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005910-17 Sponsor Protocol Number: KKSH176 Start Date*: 2021-06-01
    Sponsor Name:Martin-Luther-Universität Halle-Wittenberg
    Full Title: Phase 2 multicenter study investigating the tolerability and efficacy of UV1 vaccine in patients with recurrent or metastatic PD-L1 positive (CPS≥1) head and neck squamous cell carcinoma planned fo...
    Medical condition: Recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000736-21 Sponsor Protocol Number: HLX01-FL03 Start Date*: 2020-07-02
    Sponsor Name:Shanghai Henlius Biotech Inc.
    Full Title: A Phase 3 Multi-Centre, Randomised, Double-Blind, Parallel-Arm Study to Evaluate the Efficacy and Safety of HLX01 Versus Rituximab (Mabthera®) as First Line Treatment in Patients With Low Tumour Bu...
    Medical condition: Low tumour burden follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003899 B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-002965-39 Sponsor Protocol Number: RHMCAN0890 Start Date*: 2013-04-29
    Sponsor Name:Swiss Group for Clinical Cancer Research (SAKK)
    Full Title: Orteronel maintenance therapy in patients with metastatic castration resistant prostate cancer and non-progressive disease after first-line docetaxel therapy: A multicenter randomized double-blind ...
    Medical condition: Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002718-32 Sponsor Protocol Number: CanStem43L Start Date*: 2017-04-04
    Sponsor Name:Boston Biomedical, Inc.
    Full Title: A Phase III Randomized, Open-Label Clinical Trial of BBI-608 plus Weekly Paclitaxel versus Weekly Paclitaxel Alone in Patients with Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Ca...
    Medical condition: Histologically or cytologically confirmed recurrent, locally advanced, or metastatic non-squamous non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10066490 Progression of non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000516-25 Sponsor Protocol Number: GS-US-292-0112 Start Date*: 2013-06-04
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients with Mild to Moderate Renal Impairment
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed) DE (Completed) IT (Completed) BE (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-016826-15 Sponsor Protocol Number: BC 1.2.001 Start Date*: 2010-05-19
    Sponsor Name:CECOG
    Full Title: A phase II study evaluating the efficacy and safety of lapatinib + vinorelbine in ErbB2 positive metastatic breast cancer patients after progression of chemotherapy or hormonal treatment in combina...
    Medical condition: metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) SI (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-003762-13 Sponsor Protocol Number: NIO-0002 Start Date*: 2022-07-05
    Sponsor Name: Narodowy Instytut Onkologii im. Marii Skłodowskiej Curie – Państwowy Instytut Badawczy (NIO-PIB)
    Full Title: PHASE 1B/2 STUDY OF LIPOSOMAL ANNAMYCIN (L-ANNAMYCIN) IN PATIENTS WITH PREVIOUSLY TREATED SOFT-TISSUE SARCOMAS WITH METASTASES (ANNA-SARC)
    Medical condition: soft tissue sarcomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075333 Soft tissue sarcoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-002033-21 Sponsor Protocol Number: NKV102551 Start Date*: 2006-09-11
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Phase III Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group Study of the Efficacy and Safety of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonis...
    Medical condition: Chemotherapy induced nausea and vomiting (CINV) due to Highly Emetogenic Chemotherapy (HEC)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008448 Chemotherapy induced emesis prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed) IE (Completed) GR (Completed) BE (Completed) CZ (Completed) SK (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003428-61 Sponsor Protocol Number: GS-US-380-4449 Start Date*: 2018-04-06
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching from an Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed-Dose Combination Regimen or a Tenofovir Disoproxil Fumarate...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002125-11 Sponsor Protocol Number: CT-P13-3.5 Start Date*: 2016-08-23
    Sponsor Name:Celltrion, Inc
    Full Title: A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis
    Medical condition: Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed) HU (Completed) CZ (Completed) BG (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-008232-87 Sponsor Protocol Number: SOCS-B Start Date*: 2009-04-03
    Sponsor Name:Charite Universitätsmedizin Berlin- Campus Virchow-Klinikum
    Full Title: Open-label phase II study of sorafenib in patients with advanced hepatocellular carcinoma (HCC) and Child Pugh score B with special analysis of patients 65 years or older
    Medical condition: hepatocellular carcinoma and Child Pugh score B
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-002555-34 Sponsor Protocol Number: ECSEVO-LT-011 Start Date*: 2011-11-25
    Sponsor Name:FRANCISCO JAVIER BELDA
    Full Title: Study on the safety of administration of sevoflurane for long-term sedation in critical patients on assisted ventilation. A multicentric, randomised, controlled, prospective clinical trial.
    Medical condition: The general objective of this study is to perform an assessment of the safety of administration of sevoflurane for prolonged sedation of patients admitted to the Critical Care Unit.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10042613 Surgical and medical procedures SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-002597-33 Sponsor Protocol Number: E7070-E044-209 Start Date*: 2005-03-30
    Sponsor Name:Eisai Ltd
    Full Title: An open label dose adjustment and phase II study of E7070 in combination with capecitabine: Part 1: to determine the recommended dose of the combination Part 2: to determine the efficacy of the c...
    Medical condition: Metastatic Colorectal Cancer resistant to or unsuitable for treatment with 5-fluorouracil and irinotecan and/or oxaliplatin
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-009502-79 Sponsor Protocol Number: ipermen Start Date*: 2009-06-18
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA CAREGGI
    Full Title: open, non comparative, prospectic, phase IV clinical study to evaluate the activity and tolerance of Cinacalcet-HCl (drug name Mimpara) in patients affected by MEN1-associated primary hyperparathyr...
    Medical condition: Primary hyperparathyroidism in patients with MEN1
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020707 Hyperparathyroidism primary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003843-30 Sponsor Protocol Number: 26866138MMY2029 Start Date*: 2006-01-05
    Sponsor Name:ORTHO BIOTECH, Division of JANSSEN-CILAG GmbH
    Full Title: Bortezomib and Bendamustine in the Treatment of Refractory/Relapsed Multiple Myeloma
    Medical condition: Cytologically and/or histologically established multiple myeloma requiring treatment, stage II or III (Salmon and Durie). 1. - 3. Relapse or progression with measurable myeloma protein in the bloo...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003441-13 Sponsor Protocol Number: D8480C00021 Start Date*: 2007-07-30
    Sponsor Name:AstraZeneca AB
    Full Title: A Two-part, Open-label, Multi-centre, Phase II Study in Patients with Advanced Solid Tumours, Consisting of a Randomised 2-period Crossover Protocol to Determine the Effect of Food upon the Pharmac...
    Medical condition: Patients with advanced solid tumour
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002231-92 Sponsor Protocol Number: AP23573-04-202 Start Date*: Information not available in EudraCT
    Sponsor Name:ARIAD Pharmaceuticals, Inc.
    Full Title: A Phase II Study of AP23573, an mTOR Inhibitor, in Patients with Advanced Sarcoma
    Medical condition: Metastatic and/or unresectable soft tissue or bone sarcoma (excluding GIST).
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 24 03:09:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA